Brokerages predict that Express Scripts Holding (NASDAQ:ESRX) will report $25.13 billion in sales for the current quarter, according to Zacks. Twelve analysts have made estimates for Express Scripts’ earnings, with the highest sales estimate coming in at $25.54 billion and the lowest estimate coming in at $24.54 billion. Express Scripts posted sales of $24.86 billion during the same quarter last year, which suggests a positive year over year growth rate of 1.1%. The firm is expected to issue its next quarterly earnings report on Tuesday, February 13th.

According to Zacks, analysts expect that Express Scripts will report full year sales of $25.13 billion for the current fiscal year, with estimates ranging from $99.22 billion to $100.51 billion. For the next year, analysts anticipate that the company will report sales of $100.70 billion per share, with estimates ranging from $99.93 billion to $101.60 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Express Scripts.

Express Scripts (NASDAQ:ESRX) last posted its earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $1.90. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. The firm had revenue of $24.68 billion for the quarter, compared to analyst estimates of $25.68 billion. During the same period in the previous year, the firm posted $1.74 EPS. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year.

A number of equities research analysts have recently commented on ESRX shares. Raymond James Financial reaffirmed an “underperform” rating on shares of Express Scripts in a research note on Monday, October 9th. Zacks Investment Research lowered shares of Express Scripts from a “buy” rating to a “sell” rating in a research note on Tuesday, October 24th. Deutsche Bank started coverage on shares of Express Scripts in a research note on Monday, December 4th. They issued a “buy” rating and a $75.00 price objective on the stock. Maxim Group upped their price objective on shares of Express Scripts from $78.00 to $87.00 and gave the company a “buy” rating in a research note on Thursday, December 14th. Finally, Royal Bank of Canada set a $66.00 price objective on shares of Express Scripts and gave the company a “hold” rating in a research note on Wednesday, October 25th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Express Scripts currently has an average rating of “Hold” and a consensus price target of $74.65.

Shares of Express Scripts (NASDAQ ESRX) opened at $75.66 on Thursday. The company has a current ratio of 0.73, a quick ratio of 0.61 and a debt-to-equity ratio of 0.86. Express Scripts has a 1-year low of $55.80 and a 1-year high of $76.02. The firm has a market cap of $42,608.24, a P/E ratio of 12.46, a price-to-earnings-growth ratio of 1.00 and a beta of 0.87.

Express Scripts declared that its board has authorized a stock buyback program on Monday, December 18th that allows the company to buyback 45,000,000 outstanding shares. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

In other news, CEO Timothy C. Wentworth bought 8,000 shares of the stock in a transaction dated Tuesday, October 31st. The stock was bought at an average price of $61.13 per share, for a total transaction of $489,040.00. Following the completion of the acquisition, the chief executive officer now directly owns 98,628 shares in the company, valued at approximately $6,029,129.64. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Phyllis S. Anderson sold 643 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $62.37, for a total transaction of $40,103.91. The disclosure for this sale can be found here. Corporate insiders own 0.68% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Burt Wealth Advisors grew its position in Express Scripts by 11.4% during the second quarter. Burt Wealth Advisors now owns 1,696 shares of the company’s stock valued at $108,000 after buying an additional 174 shares during the period. Bank of Nova Scotia Trust Co. bought a new position in Express Scripts during the third quarter valued at about $120,000. First Personal Financial Services grew its position in Express Scripts by 199.1% during the second quarter. First Personal Financial Services now owns 2,103 shares of the company’s stock valued at $134,000 after buying an additional 1,400 shares during the period. Monroe Bank & Trust MI grew its position in Express Scripts by 74.8% during the third quarter. Monroe Bank & Trust MI now owns 2,266 shares of the company’s stock valued at $156,000 after buying an additional 970 shares during the period. Finally, Capstone Investment Advisors Netherlands B.V. grew its position in Express Scripts by 49.3% during the second quarter. Capstone Investment Advisors Netherlands B.V. now owns 2,797 shares of the company’s stock valued at $179,000 after buying an additional 924 shares during the period. Institutional investors own 88.28% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Express Scripts Holding (ESRX) Expected to Post Quarterly Sales of $25.13 Billion” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/04/express-scripts-holding-esrx-expected-to-post-quarterly-sales-of-25-13-billion.html.

Express Scripts Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Get a free copy of the Zacks research report on Express Scripts (ESRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.